David McKean
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David McKean has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Alison P. Klein
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, USA
16 shared publications - Anirudh Yerrapragada
Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
15 shared publications - Elana Judith Fertig
Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA
15 shared publications - Ezra Baraban
Johns Hopkins School of Medicine, Baltimore, MD
15 shared publications - Joseph Cheaib
The James Buchanan Brady Urological Institute and Department of Urology Johns Hopkins School of Medicine Baltimore Maryland USA
15 shared publications - Michael E. Rezaee
Urologic Institute at Concord Hospital, 246 Pleasant Street, Memorial Building, Concord, New Hampshire, 03301
15 shared publications
Latest Publications
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
WES QC 66 Patients (B = 34, W = 32) 123 Samples (57 T/N, 9T) RNAseq QC Avg.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
WES QC 66 Patients (B = 34, W = 32) 123 Samples (57 T/N, 9T) RNAseq QC Avg.
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
Supplementary Tables from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
Supplementary Tables from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
- Open Access
- 5 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
Supplementary Tables from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
- 5 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
Supplementary Tables from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
- Open Access
- 5 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
WES QC 66 Patients (B = 34, W = 32) 123 Samples (57 T/N, 9T) RNAseq QC Avg.
- 5 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
WES QC 66 Patients (B = 34, W = 32) 123 Samples (57 T/N, 9T) RNAseq QC Avg.
- Open Access
- 5 May 2025
- Published by American Association for Cancer Research (AACR)
Data from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
Self-reported Black (B) individuals remain underrepresented in molecular studies of clear-cell renal cell carcinoma (ccRCC) relative to White (W) individuals. We performed whole-exome and transcriptome sequencing on paired tumor and normal samples from 59 matched B and W patients undergoing nephrectomy for localized ccRCC, comparing molecular differences by estimated genetic similarity to African (AFR) and European (EUR) 1000 Genomes groups. We validated our findings with a propensity-matched subset of The Cancer Genome Atlas, yielding a final cohort of 254 patients (79 AFR and 175 EUR) with similar baseline clinical variables. Significant differences emerged in VHL mutation frequency (AFR: 23.4%, EUR: 57.5%; FDR = 0.0029) and chromosome 3p deletions (AFR: 59.2%, EUR: 82.6%; FDR = 0.086). Transcriptomic analyses identified 34 genes associated with genetic similarity, and gene set enrichment revealed inflammatory (IFN-γ/IFN-α, allograft rejection), proliferative (E2F targets, G2–M checkpoint), and metabolic (bile acid, fatty acid, glycolysis, MTORC1, peroxisome) pathway enrichment in EUR. We also observed differences in ccRCC molecular subtype distribution, with “Proliferative” and “Angio/Stromal” subtypes being more common in AFR (P = 0.018). Importantly, differential subtype membership explained most group-level differences. These results link EUR and AFR genetic similarity to distinct ccRCC molecular subtypes, underscoring the importance of molecular classifiers in disease stratification and the need to include diverse populations in molecular studies to improve our understanding and treatment of ccRCC.Significance:Our study shows that AFR genetic similarity correlates with distinct ccRCC molecular subtypes. Further research is needed to disentangle environmental and genetic influences. Identifying these differences underscores the critical importance of including racially and ethnically diverse populations in cancer research to ensure more equitable and sustainable outcomes worldwide for all patients.
- 5 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
Self-reported Black (B) individuals remain underrepresented in molecular studies of clear-cell renal cell carcinoma (ccRCC) relative to White (W) individuals. We performed whole-exome and transcriptome sequencing on paired tumor and normal samples from 59 matched B and W patients undergoing nephrectomy for localized ccRCC, comparing molecular differences by estimated genetic similarity to African (AFR) and European (EUR) 1000 Genomes groups. We validated our findings with a propensity-matched subset of The Cancer Genome Atlas, yielding a final cohort of 254 patients (79 AFR and 175 EUR) with similar baseline clinical variables. Significant differences emerged in VHL mutation frequency (AFR: 23.4%, EUR: 57.5%; FDR = 0.0029) and chromosome 3p deletions (AFR: 59.2%, EUR: 82.6%; FDR = 0.086). Transcriptomic analyses identified 34 genes associated with genetic similarity, and gene set enrichment revealed inflammatory (IFN-γ/IFN-α, allograft rejection), proliferative (E2F targets, G2–M checkpoint), and metabolic (bile acid, fatty acid, glycolysis, MTORC1, peroxisome) pathway enrichment in EUR. We also observed differences in ccRCC molecular subtype distribution, with “Proliferative” and “Angio/Stromal” subtypes being more common in AFR (P = 0.018). Importantly, differential subtype membership explained most group-level differences. These results link EUR and AFR genetic similarity to distinct ccRCC molecular subtypes, underscoring the importance of molecular classifiers in disease stratification and the need to include diverse populations in molecular studies to improve our understanding and treatment of ccRCC.Significance:Our study shows that AFR genetic similarity correlates with distinct ccRCC molecular subtypes. Further research is needed to disentangle environmental and genetic influences. Identifying these differences underscores the critical importance of including racially and ethnically diverse populations in cancer research to ensure more equitable and sustainable outcomes worldwide for all patients.
- Open Access
- 1 May 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
AFR and EUR groups are associated with a distinct tumor microenvironment composition. A, Heatmap of xCell results performed on the pooled analytic cohort (n = 78 AFR and n = 175 EUR). Values are row-scaled xCell enrichment scores for lymphoid, myeloid, and stromal cell types (n = 38 cell types). B, Box plots depict xCell enrichment scores for differentially enriched cell types. Box plot borders depict the median, upper quartile, and lower quartile. P values were determined by the Kruskal–Wallis test with multiple hypothesis correction. Statistical significance is as follows: *, P <0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. aDC, activated dendritic cell; cDC, conventional dendritic cell; DC, dendritic cell; ES, enrichment score; iDC, immature dendritic cell; NKT, NK T cell; pDC, plasmacytoid dendritic cell; Tcm, central memory; Tem, effector memory; Tgd, gamma–delta T cell; Treg, regulatory T cell.
- 1 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
AFR and EUR groups are associated with a distinct tumor microenvironment composition. A, Heatmap of xCell results performed on the pooled analytic cohort (n = 78 AFR and n = 175 EUR). Values are row-scaled xCell enrichment scores for lymphoid, myeloid, and stromal cell types (n = 38 cell types). B, Box plots depict xCell enrichment scores for differentially enriched cell types. Box plot borders depict the median, upper quartile, and lower quartile. P values were determined by the Kruskal–Wallis test with multiple hypothesis correction. Statistical significance is as follows: *, P <0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. aDC, activated dendritic cell; cDC, conventional dendritic cell; DC, dendritic cell; ES, enrichment score; iDC, immature dendritic cell; NKT, NK T cell; pDC, plasmacytoid dendritic cell; Tcm, central memory; Tem, effector memory; Tgd, gamma–delta T cell; Treg, regulatory T cell.
- Open Access
- 1 May 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
CcRCC driver mutations by AFR and EUR groups, race, and RCC clinical risk factors. A, OncoPrint of ccRCC driver mutations split by AFR and EUR groups. B, Frequency of VHL mutations in patients by HTN history, eGFR group, and self-reported race. Group-wise P values were calculated using Fisher’s exact test. Mut, mutant; SNV, single nucleotide variant; Wt, wild-type.
- 1 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
CcRCC driver mutations by AFR and EUR groups, race, and RCC clinical risk factors. A, OncoPrint of ccRCC driver mutations split by AFR and EUR groups. B, Frequency of VHL mutations in patients by HTN history, eGFR group, and self-reported race. Group-wise P values were calculated using Fisher’s exact test. Mut, mutant; SNV, single nucleotide variant; Wt, wild-type.
- Open Access
- 1 May 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
VHL mutation status is associated with both molecular subtype and genetic similarity. A, OncoPrint of ccRCC driver mutations split by IMm151 molecular subtype. P values were calculated using Fisher’s exact test. B, Frequency of VHL mutations in patients by IMm151 molecular subtype and AFR/EUR grouping. P values were calculated using Fisher’s exact test. Mut, mutant; SNV, single nucleotide variant; wt, wild-type.
- 1 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
VHL mutation status is associated with both molecular subtype and genetic similarity. A, OncoPrint of ccRCC driver mutations split by IMm151 molecular subtype. P values were calculated using Fisher’s exact test. B, Frequency of VHL mutations in patients by IMm151 molecular subtype and AFR/EUR grouping. P values were calculated using Fisher’s exact test. Mut, mutant; SNV, single nucleotide variant; wt, wild-type.
- Open Access
- 1 May 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
Clinicopathologic characteristics of case–case-matched cohort
- 1 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
Clinicopathologic characteristics of case–case-matched cohort
- Open Access
- 1 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
Supplementary Tables from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
- 1 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity
Supplementary Tables from Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity